MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • The Challenge Of Tackling MDS/MPN
    Hello, I'm Michael Savona from Vanderbilt University Medical Center, here to talk about the challenge of tackling MDS/MPN at the SOHO Fourth Annual Meeting in Houston, Texas.
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Biology and Targeting of Eosinophilic MPNs
    Hi, I'm Jason Gotlib. I'm at the Stanford Cancer Institute in Stanford, California, and I'm excited to be here at SOHO 2016. I'm going to be talking about the biology and targeting of eosinophilic MPNs.
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • What Does This Patient Have: ET, PV or Masked PV?
    What does this patient have? Essential thrombocythemia, polycythemia vera, or masked polycythemia vera? The purpose of this talk is to get some definitions of polycythemia vera and the concept of masked polycythemia vera through a clinical presentation and looking at the specific importance of bone marrow morphology and, finally, the implications for revising diagnostic criteria.
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Case Presentation #2
    My name is Michael Grunwald. I’m a leukemia specialist at the Levine Cancer Institute in Charlotte, North Carolina and I’m presenting a case study in polycythemia vera. To summarize, this case illustrates one type of hydroxyurea failure, namely the occurrence of significant cytopenias in the context of hydroxyurea treatment. The patient also happened to have intolerance of pegylated interferon. R...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Case Presentation #1
    Hello. My name is Srdan Verstovsek. I am a professor of medicine in the leukemia department at MD Anderson Cancer Center in Houston, Texas. Today I want to speak to you about polycythemia vera. This case illustrates two aspects of possible inadequate response to hydroxyurea interacting in PV. Intolerance, that is, a skin ulcer, and resistance, uncontrolled myeloproliferation and presence of syste...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Self-Reported Quality of Life Impairment in PV: Insights from REVEAL
    My name is Michael Grunwald. I’m a leukemia specialist at the Levine Cancer Institute in Charlotte, North Carolina. I’m going to be talking about self-reported quality-of-life impairment in polycythemia vera, insights from REVEAL. To summarize, PV patients enrolled in REVEAL have high symptom burdens leading to physical and emotional qualify-of-life impairment. The symptom burden of polycythemia ...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • What is the Impact on Quality of Life in PV Patients?
    Today I want to speak to you about the impact on quality of life in PV patients. In summary, we’ve discussed that patients with PV present with a complex constellation of symptoms and that such symptoms have a major impact upon quality of life for many PV sufferers. We’ve also seen recent data supporting that symptoms can correlate with features of higher risk disease, for example, hydroxyurea fa...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Cross-Functional Collaboration in Managing PV Patients
    Hello, my name is Jeff Bryan and I’m a clinical pharmacist with the leukemia service at M.D. Anderson Cancer Center. I want to thank you for joining this presentation about a multidisciplinary care approach to managing patients with polycythemia vera and essential thrombocythemia, which I will refer to as PV and ET. In summary, some of the potential benefits of a multidisciplinary care approach f...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • How Do We Approach the Problematic PV Patient?
    Today's program will focus on the patient with more problematic polycythemia vera. Take home points, failure of hydroxyurea as frontline for patients with PV is usually on the basis of resistance or intolerance. Two, patients who fail hydroxyurea have a more adverse prognosis than higher symptom burden. Three, ruxolitinib is approved as second-line therapy in PV patients and one can expect contro...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Managing Vascular Events in Patients with PV
    In today's program, we’re going to be focusing around frontline therapy of patients with p-vera, in particular, in those that have had vascular events. The take-home points for management of patients with p-vera. All p-vera patients require control of hematocrit and anti-platelet therapy. Two, frontline cytoreduction is hydroxyurea for p-vera, although the data we have is fairly modest and there ...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Perspectives and Future Directions in ET and PV
    My name is Heinz Gisslinger from the Medical University of Vienna, and I am presenting at the SOHO 2016 meeting about perspectives and future directions in essential thrombocythemia and polycythemia vera.
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Novel Agents and Combination Strategies in MF
    I'm Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center in New York. I'm going to be talking about novel agents and therapeutic strategies in myelofibrosis. We'll be covering the current treatment landscape as well as new approaches, including current clinical trials of novel agents and combinatorial approaches. We’ll also talk about preclinical models that may soon be able to be bro...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Animal Models of MPN - What Do They Teach Us?
    Dr. Rick Van Etten, MPNs, Myeloproliferative Neoplasm, Melanoma, Hematology, Oncology, Leukemia, bloodcancer, clinical, mouse models, clinical utility, chronic myeloid leukemia, CML, pathophysiology, treatment, patients, tyrosine kinase inhibitor therapy, therapy,
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Panobinostat-RUX in MF: Is Combination the Future of Treatment?
    In summary, from the data we currently have available, we can conclude that the combination of ruxolitinib and panobinostat is well tolerated. Although we haven’t looked at it specifically in detail in this presentation, I can share with you that anemia, thrombocytopenia, and diarrhea were the most common adverse events, but these were well controlled and consistent with those observed with ruxoli...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • How Does Anemia Impact Overall Survival in Myelofibrosis?
    In conclusion, disease-related anemia is a powerful negative prognostic factor both at a time of diagnosis and even more so as it develops during the course of the disease. Red blood cell transfusion dependency may further worsen a patient’s outcome if it is a disease-related development. I’ve highlight disease-related development because some of the medications that we use may worsen the anemia a...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • ReTHINK: A Phase 3 Study of Ruxolitinib in Early Myelofibrosis Patients
    Hi. My name is Alessandro Vannucchi, and I'm an associate professor of hematology at the University of Florence. The topic of this short presentation is about the ReTHINK study; that is a phase 3 study of ruxolitinib in early myelofibrosis patients. We know that myelofibrosis is a progressive disease. Indeed, if you compare patients at diagnosis with those seen after 1 year of diagnosis, the prop...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Multidisciplinary Care Approach in Myelofibrosis
    Hello, my name is Jeff Bryan and I’m a clinical pharmacist with the leukemia service at MD Anderson Cancer Center. I want to thank you for joining this presentation about a multidisciplinary care approach to managing myelofibrosis.
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • The JUMP Study and Its Impact in Practice
    To conclude, this first set of data from the JUMP study that includes the largest cohort of patients with myelofibrosis that have received ruxolitinib to date, and also includes this specific subcategory of patients with intermediate-1 risk myelofibrosis, supports that ruxolitinib is overall well tolerated. In light of the fact that the most common adverse events are represented by anemia and thro...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • What Have We Learned from the EXPAND Study?
    So, in conclusion, this interim analysis from the EXPAND studies strengthens the idea that ruxolitinib can be safely administered in patients with MF and thrombocytopenia starting with a lower dose, as of course, in patients with platelets higher than 100,000. The kind and the number of adverse events that have been observed in this population were no different from what was expected from the acti...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Identifying Early-Stage MF: Who, What, How?
    In summary prefibrotic myelofibrosis is a new entity in WHO classifications of myeloproliferative neoplasms. Its identification relies heavily on specific bone marrow characteristics and prefibrotic myelofibrosis therefore maybe sometimes difficult to separate from ET. The bone marrow exam is a key. Clinical outcome of prefibrotic myelofibrosis is worse than ET but much better than in patients wit...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Escape from Cytoreduction: How Do We Identify Disease Progression?
    I’m Dr. Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York. Today we’ll be talking about escaping from cytoreduction, how to identify disease progression in patients with polycythemia vera. To conclude, despite therapy with cytoreduction agents, patients may experience disease progression. Patients may escape from the effects of cytoreduction in several ways, which include dise...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Understanding the Importance of Baseline Patient Features in the RESPONSE-2 Study
    Hi. My name is Alessandro Vannucchi and I’m an associate professor of hematology at the University of Florence. Here I’d like to discuss with you about the main characteristics of the RESPONSE-2 study, especially focusing on the characteristics of the patients who have been enrolled in this study. To do this, I will somewhat jump between this study and the previous one, the RESPONSE study, that h...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • The Role and Interpretation of JAK Mutational Screening in PV
    In summary, the JAK-STAT pathway hyperactivity is the main biological abnormality in PV, as is in other myeloproliferative neoplasms. Almost all patients with PV have mutation in JAK2 gene, either in JAK2 V617F, which is the great majority of the patients, or in JAK2 exon 12 mutations in a few percentage points. There is no difference in their outcome based on the mutational profile, and identific...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • Early Insights from the REVEAL Study
    I'm Michael Grunwald, I’m a leukemia specialist at the Levine Cancer Institute in Charlotte, North Carolina. I’m speaking about early insights from the REVEAL study: clinical features of polycythemia vera. The REVEAL study is a perspective observational study of patients with polycythemia vera in United States clinical practices. It is a multi-center non-interventional, non-randomized, prospective...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • The Current State of Treating PV: A Minute Overview
    I’m Doctor Raajit Rampal from Memorial Sloan Kettering Cancer Center in New York. Today, we're going to be talking about the current state of treating polycythemia vera. Retrospective studies of patients with polycythemia vera have demonstrated that patients with PV do have a decreased life span as compared to the general population. As well, there is a risk of thrombosis, which represents the mo...
MPNUniversity.tv
MPNUniversity.tv
YouTube Video

New YouTube videos detected.

  • New Drugs in Pipeline for Myelofibrosis
    Take-home points? Pacritinib and momelotinib have completed phase 3 clinical trials and seek a role based on incremental benefit and safety, and patients with cytopenia; two, PRM-151 and imetelstat are the most mature of the non-JAK inhibitors in the pipeline of therapies from myelofibrosis; and, three, second-line therapy for MF is surely the most wide-open need, and any of these agents may poten...

Out-Market Your Competitors?

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account Log in

By signing up, you agree to the Terms of Service and Privacy Policy.

Out-Market Your Competitors

Get complete competitive insights on over 2.2 million companies to drive your marketing strategy.

Create Free Account

Already a user?  Log in

By signing up, you agree to the Terms of Service and Privacy Policy.